Absci (NASDAQ:ABSI – Get Free Report) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.
ABSI has been the subject of a number of other research reports. Needham & Company LLC raised their price objective on shares of Absci from $11.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 12th. HC Wainwright reiterated a “buy” rating on shares of Absci in a research note on Tuesday, October 20th. JPMorgan Chase & Co. increased their target price on shares of Absci from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. BTIG Research restated a “buy” rating and set a $16.00 price target on shares of Absci in a research note on Thursday, November 12th. Finally, Jefferies Financial Group initiated coverage on shares of Absci in a research note on Thursday, October 29th. They set a “buy” rating and a $14.00 price target for the company. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.90.
View Our Latest Report on ABSI
Absci Trading Down 8.0%
Absci (NASDAQ:ABSI – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.66 million. Absci had a negative net margin of 8,451.31% and a negative return on equity of 61.60%. On average, research analysts forecast that Absci will post -0.76 EPS for the current year.
Hedge Funds Weigh In On Absci
A number of institutional investors have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC raised its position in shares of Absci by 6.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 25,763 shares of the company’s stock valued at $277,000 after buying an additional 1,484 shares in the last quarter. Profund Advisors LLC increased its position in shares of Absci by 4.0% during the 3rd quarter. Profund Advisors LLC now owns 75,705 shares of the company’s stock valued at $815,000 after purchasing an additional 2,916 shares during the last quarter. Cetera Investment Advisers raised its holdings in shares of Absci by 30.6% during the 3rd quarter. Cetera Investment Advisers now owns 14,349 shares of the company’s stock valued at $155,000 after buying an additional 3,358 shares in the last quarter. AXQ Capital LP raised its holdings in shares of Absci by 10.5% during the 2nd quarter. AXQ Capital LP now owns 36,000 shares of the company’s stock valued at $417,000 after buying an additional 3,435 shares in the last quarter. Finally, Sterling Capital Management LLC raised its holdings in shares of Absci by 433.7% during the 3rd quarter. Sterling Capital Management LLC now owns 4,622 shares of the company’s stock valued at $50,000 after buying an additional 3,756 shares in the last quarter. 52.05% of the stock is currently owned by institutional investors.
Absci Company Profile
Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.
See Also
- Five stocks we like better than Absci
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
